Cargando…
Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
Toripalimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). It has recently been approved as an immune checkpoint inhibitor in second-line therapies in patients with unresectable or metastatic melanoma; however, it may be associated with various immune-related adverse even...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367952/ https://www.ncbi.nlm.nih.gov/pubmed/32445174 http://dx.doi.org/10.1007/s13555-020-00396-6 |